Here we used a murine model of ALCL, driven by the expression of the human fusion oncogene NPM::ALK in T cells, to assess the effects of pharmacological inhibition or genetic deletion of specific class I HDAC isoforms. This evidence concerns the gene HDAC9 and anaplastic large cell lymphoma.